search button

Expression signature of ten genes predicts the survival of patients with estrogen receptor positive‑breast cancer that were treated with tamoxifen

  • Authors:
    • He Huang
    • Qiyu Chen
    • Weijian Sun
    • Mingdong Lu
    • Yaojun Yu
    • Zhiqiang Zheng
    • Pihong Li

  • View Affiliations

  • Published online on: May 8, 2018     https://doi.org/10.3892/ol.2018.8663
  • Pages: 573-579
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Although tamoxifen is the most frequently used drug for the treatment of estrogen receptor positive (ER+)‑breast cancer (BRCA), its efficacy varies between patients. In the present study, Cox multivariate regression of the relative mRNA expression levels in two microarray‑based datasets (GSE17005 and GSE26971) was employed to develop a risk score model to evaluate the outcome of patients with BRCA in the GSE17005 dataset. A total of ten genes were used to develop the prediction model for the survival of tamoxifen‑treated patients with breast cancer. The survival time of patients in the low risk score group was significantly longer compared with patients in the high risk score group. This observation was validated in three other datasets (GSE26971, GSE22219 and GSE56884). The prognostic effect of the clinicopathological indicators and the risk score were tested with the 5‑year event receiving operating characteristic curve, and the risk score had an improved prognostic value in patients with ER+‑BRCA with an area under the curve value of 0.733 compared with the factors of age, tumor stage, tumor grade, chemotherapy, lymph invasion and tumor size. The risk score was significantly associated with the tumor‑node‑metastasis stage and grade, but was independent of age, sex, lymph invasion and tumor size. In summary, the risk model for breast cancer using the expression signature of ten genes may be an important indicator for predicting the survival of patients with ER+‑breast cancer and treated with tamoxifen.
View Figures
View References

Related Articles

Journal Cover

July-2018
Volume 16 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Huang H, Chen Q, Sun W, Lu M, Yu Y, Zheng Z and Li P: Expression signature of ten genes predicts the survival of patients with estrogen receptor positive‑breast cancer that were treated with tamoxifen. Oncol Lett 16: 573-579, 2018.
APA
Huang, H., Chen, Q., Sun, W., Lu, M., Yu, Y., Zheng, Z., & Li, P. (2018). Expression signature of ten genes predicts the survival of patients with estrogen receptor positive‑breast cancer that were treated with tamoxifen. Oncology Letters, 16, 573-579. https://doi.org/10.3892/ol.2018.8663
MLA
Huang, H., Chen, Q., Sun, W., Lu, M., Yu, Y., Zheng, Z., Li, P."Expression signature of ten genes predicts the survival of patients with estrogen receptor positive‑breast cancer that were treated with tamoxifen". Oncology Letters 16.1 (2018): 573-579.
Chicago
Huang, H., Chen, Q., Sun, W., Lu, M., Yu, Y., Zheng, Z., Li, P."Expression signature of ten genes predicts the survival of patients with estrogen receptor positive‑breast cancer that were treated with tamoxifen". Oncology Letters 16, no. 1 (2018): 573-579. https://doi.org/10.3892/ol.2018.8663